是否有矛盾？

An angiotensin-converting enzyme inhibitor or angiotensin receptorneprilysin inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a sodium-glucose co-transporter 2 inhibitor are recommended as cornerstone therapies to reduce mortality and heart failure (HF) hospitalizations for all patients with HF with reduced ejection fraction and may be considered in patients with HF with mildly reduced ejection fraction.

推荐血管紧张素转换酶抑制剂或血管紧张素受体抑制剂、β受体阻滞剂、盐皮质激素受体拮抗剂和钠-葡萄糖协同转运体2抑制剂用于所有射血分数降低的心衰患者，作为降低死亡率和心力衰竭（HF）住院的基石疗法，并可考虑用于射血分数轻度降低的心衰患者。

既然所有的射血分数降低的心衰患者都推荐，为啥射血分数轻度降低的心衰患者只是考虑，是否有矛盾